Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.45 |
| ▸ | ACP3 | P15309 | 2/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CETP | P11597 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25853632 | 0.82 | SLC6A4 (0.56) | PNMTSLC6A2SLC6A4CES2ACP3 | |
| SCHEMBL30353293 | 0.82 | CNR2 (0.58) | PNMTGRIN2BACP3CETP | |
| SCHEMBL30034816 | 0.82 | CNR2 (0.58) | PNMTGRIN2BACP3CETP | |
| SCHEMBL22817596 | 0.82 | CNR2 (0.58) | PNMTGRIN2BACP3CETP | |
| SCHEMBL22817603 | 0.82 | CNR2 (0.58) | PNMTGRIN2BACP3CETP | |
| SCHEMBL22817597 | 0.82 | CNR2 (0.58) | PNMTGRIN2BACP3CETP | |
| SCHEMBL4669029 | 0.81 | PNMT (0.70) | PNMTCES2GRIN2BACP3 | |
| SCHEMBL30728210 | 0.81 | PNMT (0.70) | PNMTCES2GRIN2BACP3 | |
| SCHEMBL11633779 | 0.81 | SLC6A2 (0.52) | PNMTSLC6A2SLC6A4CES2ACP3 | |
| SCHEMBL25300306 | 0.81 | SLC6A2 (0.54) | PNMTSLC6A2SLC6A4CES2ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2026-02-12 | — | — | US | disclosed |
| EP-4463453-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2024-11-20 | — | — | EP | disclosed |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2024-09-19 | — | — | US | disclosed |
| CN-118541370-A | Azaindole derivatives and their use as ERK kinase inhibitors | AGV探索公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | AGV DISCOVERY (FR) | 2023-11-28 | — | — | US | disclosed |
| WO-2023135233-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | WO | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV DISCOVERY (FR) | 2023-07-20 | — | — | US | disclosed |
| EP-4212531-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | AGV Discovery (FR) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827637-B2 | Azaindole derivatives and their use as ERK kinase inhibitors | MAPKAPK2, MAPK1, MAPK7 | PNMT 721/4885SLC6A2 1803/4885SLC6A4 2807/4885 |
| US-20260042758-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | BRAF, RAF1, NRAS | PNMT 3081/4885SLC6A2 3736/4885SLC6A4 4506/4885 |
| US-20230227451-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | PNMT 721/4885SLC6A2 1803/4885SLC6A4 2807/4885 |
| US-20240308997-A1 | AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK7 | PNMT 721/4885SLC6A2 1803/4885SLC6A4 2807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.